Black Rock Inc. Caladrius Biosciences, Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.48 - $7.8 $409,259 - $6.65 Million	-852,624 Closed	0 $0
Q2 2022 Aug 12, 2022	SELL	$0.41 - $0.74 $61,194 - $110,448	-149,255 Reduced 14.9%	852,624 $452,000
Q1 2022 May 12, 2022	SELL	$0.63 - $1.03 $4,501 - $7,360	-7,146 Reduced 0.71%	1,001,879 $723,000
Q4 2021 Feb 10, 2022	BUY	$0.83 - $1.22 $6,568 - $9,655	7,914 Added 0.79%	1,009,025 $849,000
Q3 2021 Nov 09, 2021	BUY	$1.15 - $1.57 $58 - $80	51 Added 0.01%	1,001,111 $1.22 Million
Q2 2021 Aug 11, 2021	BUY	$1.4 - $1.9 $1.4 Million - $1.9 Million	1,001,060 New	1,001,060 $1.61 Million

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.